Thus, we tested the influence of CLO on CLL B cell response to i) the purine analogue Fludarabine; ii) the inhibitor of the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, Venetoclax; iii) the inhibitor of the Bruton Tyrosine Kinase, Ibrutinib [31, 32]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.